BRIEF: C-MER swings to the red on $26 million in charges
C-MER Medical Holdings Ltd. (3309.HK) said it expects to report its revenue was flat last year compared with 2023, as it swung into the red after taking about HK$200 million…
BRIEF: Ascentage Pharma prices U.S. IPO at 20% discount, to raise up to $130 million
Biopharmaceutical company Ascentage Pharma Group International (6855.HK) announced Friday that it will offer 7.325 million American Depositary Shares (ADS) in its upcoming U.S. listing at an issue price of $17.25…
BRIEF: Qyuns Therapeutics secures CSRC approval for full H-share circulation
Biopharmaceutical company Qyuns Therapeutics Co. Ltd. (2509.HK) announced on Tuesday that the China Securities Regulatory Commission (CSRC) has approved its plan to convert 17.32 million of its domestic shares into…
BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
Biopharmaceutical company InnoCare Pharma Ltd. (9969.HK; 688428.SH) announcedon Monday that it, along with KeyMed (2162.HK) and their joint venture have signed a licensing deal for one of their products with…
BRIEF: Abbisko moves into the black in 2024
Biopharmaceutical company Abbisko Cayman Ltd. (2256.HK) said on Monday that its revenue increased significantly last year, up from 19 million yuan ($2.59 million) in 2023 to 485 million yuan in…
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
InnoCare Pharma Ltd. (9969.HK; 688428.SH) said on Thursday its revenue rose 37% last year to 1.01 billion yuan ($138 million), fueled by strong gains for Orelabrutinib, its drug used to…
BRIEF: China Traditional Chinese Medicine’s profit tumbles in 2024
China Traditional Chinese Medicine Holdings Co. Ltd. (0570.HK) on Wednesday warned that it expects to report its profit for all of 2024 fell by 90% to 100%, while its adjusted…